Of note, FTis are only in clinical phase II trials for HRAS mutant head and neck cancers (clinicaltrials.gov ID: NCT03496766; NCT02383927; NCT03719690) and are not clinically approved for other diseases in contrast to statins and N-bisphosphonates. The gene discussed is HRAS; the disease is head and neck cancer.